Cooper, CurtisCanadian Journal of Addiction
drug manufacturer Gilead Sciences announced their new hepatitis C treatment -- Sovaldi -- has a cure rate of up to 90 percent.But this therapy would cost patients $1,000 a day. AbbVie, another pharmaceutical company, plans to unveil their hepatitis C treatment later...
This study explored a novel treatment method for HAE infringing on the IVC and evaluated the safety and feasibility of combined resection of the liver and the IVC. A total of 13 patients were treated with liver resection combined with IVC resection for end-stage HAE between January 2016 and ...
Aggressively scaling up testing and treatment of hepatitis C virus (HCV) among HIV-positive men who have sex with men (MSM) in Melbourne was associated with a steep decline in hep C in this demographic, aidsmap reports. HCV is commonly transmitted through condomless sex among MSM, as well...
a, Western blot of SOAT1 and SOAT2 in PLC/PRF/5 and HepG2 cell lines, with or without treatment with shRNA (n = 3 biologically independent experiments). For full scans, see Supplementary Fig. 1. b, c, SOAT1 protein abundance in PLC/PRF/5 and HepG2 cells based on proteomic data...
Investigations on further, similar compounds, like derivatives of bhimamycins H and I, could be of interest for the discovery of new drugs for the treatment of the chronic obstructive pulmonary disease.24 The diversity and multitude of aromatic polyketides and polyketide shunt products isolated from...
Accordingly, a better understanding of the pathogenesis of NAFLD is critical for gaining new insight into the regulatory network of NAFLD and for identifying new targets for the prevention and treatment of NAFLD. In this review, we emphasize on the current understanding of the inter-organ ...
The in vitro activity of a new analogue of 2-alkenylquinoline (2-nitrilquinoline or NQ) against Leishmania donovani was compared to oral reference drug miltefosine (HePC). IC 50 of NQ was found at 38.6 μM against promastigotes and 2.4 μM against intramacrophage amastigotes. In vivo evaluat...
Many studies of hospitalized COVID-19 patients, including our study, suffer from important limitations. First, confounding variables exist including heterogeneous demographics, medications at hospitalization, individualized treatment approaches, and, in some cases, unknown history of pre-existing medical or ...
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences. A panel of California medical experts voted Monday that...